openPR Logo
Press release

Parenteral Drugs Market to Exhibit 6% CAGR, on Back of Surging Demand for Self-administered Drugs Finds Fact.MR

05-05-2021 05:56 AM CET | Health & Medicine

Press release from: Fact.MR

The research study encompasses nitty-gritty of the global parenteral drugs market, from future prospects to the competitive scenario, comprehensively. With DROT analysis and Porter’s Five Forces analysis, the authors have presented a platter of factors influencing the growth of the parenteral drugs market. Further, the parenteral drugs market has been broken down into various segments, regions, end-uses and players to provide a clear picture of the present market situation to the readers.

Click HERE to Get Synopsis of the Report- https://www.factmr.com/report/3189/parenteral-drug-market

Reports at discounted rates for new entrants!!! Purchase ASAP before the offer ends!!!

Self-administered drugs through pre-filled syringes offer opportunities to reduce consumer spending on caregiver fees. Furthermore, manufacturers are gaining sharper profit margins with the introduction of this drug delivery medium in their portfolio. On this backdrop, the global parenteral drugs market estimated at US$ 451 Bn in 2019, is projected to witness moderate growth during the forecast period (2019 – 2029).

For detailed insights on enhancing your product footprint, request for a sample here- https://www.factmr.com/connectus/sample?flag=S&rep_id=3189

Drugs for cancer are always short in supply in countries where the market is monopolistic and access to such medicines is dominated by a single player. Rising prevalence of chronic illnesses such as cancer, cardiovascular diseases, and diabetes, across the globe has been the prime revenue driver for parenteral drugs and this trend is not likely to abate any time in the foreseeable future.

Key Takeaways of Parenteral Drugs Market Study

By product type, monoclonal antibodies segment accounts for maximum market share in terms of revenue in the parenteral drugs market. This is primarily attributed to the rising adoption of biologics and subsequent rise in the number of biologics approved for marketing.

North America and Europe collectively hold over 60% of the parenteral drugs market share owing to the rise in new product launches in the regions.
Hospital pharmacies segment is expected to be the dominant distribution channel in the parenteral drugs market.

The parenteral drugs market is highly fragmented. Some of the prominent parenteral drug manufacturers include, Merck & Co. Inc., Teva Pharmaceutical Industries Ltd., Sanofi S.A., Novartis AG, and Pfizer Inc., among many others.

Need more information about Report Methodology? Click here- https://www.factmr.com/connectus/sample?flag=RM&rep_id=3189

“Patent expiration of branded products and fewer new product launches have resulted in the rise of generic versions of drugs, and in the emergence of a number of players in the market – this factor has intensified total parenteral drugs sales,” says a Fact.MR analyst.

Increased Research Funding to Drive Parenteral Drugs Market Growth

Research funding has surged significantly in recent years, which has resulted in an increase in the number of projects undertaken as well as newly employed personnel for the same. The funding for research comes from governments, private players, and other commercial entities. For instance,

In 2017, the National Cancer Institute (NCI) received over US$ 5.6 billion for research initiatives, which reflects a 7% increase as compared to 2016.
Similarly, in 2018, in the U.S., the Omnibus Appropriations bill that provided additional funding of US$ 3 billion for the NIH (National Institutes of Health) was passed, which is the highest increase in NIH funding in the past 15 years. This boost in funding, which brings the total NIH investment to US$ 37.1 billion for FY 2018, is expected to speed up cancer research in the coming years.

The expected trend indicates a significant rise in NIH funding in the fiscal year 2017 – 2018. In the future, investments in R&D are likely to increase in all countries across the world, especially in countries such as China and Brazil.

Full Access of this Exclusive Report is Available at- https://www.factmr.com/checkout/3189/S

Looking for More Information?

The research study on parenteral drugs market by Fact.MR incorporates an unbiased assessment of key demand-driving factors and trends, which have shaped the landscape of parenteral drugs over 2014 – 2018 and includes a detailed assessment of key parameters that are anticipated to exert influence over 2019 – 2029. Market statistics have been presented on the basis of product type (monoclonal antibodies, immunoglobulin, cytokines, indulin, peptide harmones, blood factors, peptide antibiotics, vaccines, small molecule antibiotics, chemotherapy agents, and others), application (oncology, infectious diseases, diabetes, hormonal disorders, musculoskeletal disorders, CNS diseases, pain management and cardiovascular diseases), route of administration (intravenous, intramuscular and subcutaneous), and distribution channel (hospital pharmacies, retail pharmacies, drug stores and online pharmacies) across seven major regions.

For More Insights: https://www.biospace.com/article/rising-cases-of-cardiovascular-diseases-fuelling-fractional-flow-reserve-computed-tomography-ffr-ct-demand-fact-mr/

US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583

Corporate Headquarter:
Unit No: AU-01-H Gold Tower (AU),
Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers,
Dubai, United Arab Emirates
Email : sales@factmr.com
Website : https://www.factmr.com
Research Insight: https://www.factmr.com/report/3189/parenteral-drug-market
Content Source: https://www.factmr.com/media-release/1226/global-parenteral-drug-market

About Fact.MR
Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions.
We have offices in US and Dublin, whereas our global headquarter is in Dubai.While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise.
Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed.
Reach out to us with your goals, and we’ll be an able research partner.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Parenteral Drugs Market to Exhibit 6% CAGR, on Back of Surging Demand for Self-administered Drugs Finds Fact.MR here

News-ID: 2279984 • Views:

More Releases from Fact.MR

Insulated Drinkware Market to Hit USD 2.57 Billion by 2033 | YETI, Thermos L.L.C., Hydro Flask Lead - Fact.MR
Insulated Drinkware Market to Hit USD 2.57 Billion by 2033 | YETI, Thermos L.L.C …
The global insulated drinkware market was valued at US$ 1.39 billion in 2023 and is forecasted to expand at a 6.3% CAGR over the next ten years. Worldwide sales of insulated drinkware are projected to reach US$ 2.57 billion by 2033-end.This robust growth is driven by increasing consumer awareness of sustainability, rising participation in outdoor activities, and the growing demand for reusable, eco-friendly products amid bans on single-use plastics. The market
Digital Twin Market is Growing at a CAGR of 34.3% d by 2033 | Key Players: ABB Ltd, ANSYS, Inc, AT&T Inc, AVEVA Group plc, Bentley Systems
Digital Twin Market is Growing at a CAGR of 34.3% d by 2033 | Key Players: ABB L …
Digital Twin Market is valued at USD 5 billion in 2023 and is projected to expand at a compound annual growth rate (CAGR) of 34.3%, reaching USD 95 billion by 2033. This explosive growth is driven by the increasing adoption of digital twins across industries to optimize operations, reduce costs, and enhance decision-making through virtual replicas of physical assets. Digital twins integrate IoT, AI, and data analytics to simulate real-world
Hemato Oncology Testing Market is Forecasted to Reach USD 23.64 Billion by 2033 | Fact.MR Report
09-02-2025 | Health & Medicine
Fact.MR
Hemato Oncology Testing Market is Forecasted to Reach USD 23.64 Billion by 2033 …
The global hemato oncology testing market is valued at USD 4.33 billion in 2023 and is projected to expand at a compound annual growth rate (CAGR) of 18.5%, reaching USD 23.64 billion by 2033. This rapid growth is driven by the increasing prevalence of blood-related cancers, such as lymphoma and leukemia, and advancements in diagnostic technologies like next-generation sequencing (NGS) and polymerase chain reaction (PCR). Hemato oncology testing plays a
Osseointegration Implants Market is Anticipated to Reach USD 6.85 Billion by 2035
09-02-2025 | Health & Medicine
Fact.MR
Osseointegration Implants Market is Anticipated to Reach USD 6.85 Billion by 203 …
Osseointegration Implants Market is poised for robust growth, with its valuation projected to rise from USD 3.17 billion in 2025 to USD 6.85 billion by 2035, reflecting a compound annual growth rate (CAGR) of 8%. This expansion is driven by the increasing prevalence of orthopedic and dental disorders, such as osteoarthritis, rheumatoid arthritis, and edentulism, which necessitate advanced implant solutions. Osseointegration implants, which fuse directly with bone to provide stable

All 5 Releases


More Releases for NIH

AICUP to Congress: NIH/NSF Research Fuels Pennsylvania's Economy
"AICUP TO CONGRESS: NIH/NSF RESEARCH FUELS PENNSYLVANIA'S ECONOMY" Letter to Pennsylvania Congressional Delegation on Behalf of 85 Independent Nonprofit Colleges and Universities Spotlights the Crucial Role of Research Funding in Modern Life, American Prosperity For Immediate Release
Creative Biolabs Shines at the 2024 NIH Research Festival: Showcasing Antibody S …
Creative Biolabs made a splash at the 2024 NIH Research Festival, held from Sept. 23 to 25, as they highlighted their groundbreaking work in antibody discovery and development. New York, USA - October 9, 2024 - The festival, which featured scientific lectures, poster presentations, and workshops, was a vibrant hub of knowledge exchange, and Creative Biolabs took center stage in presenting their cutting-edge antibody solutions. Image: https://www.getnews.info/uploads/b920cc86d613e54736218c29e7f29b5b.jpg One of the standout technologies on
Omnix Medical Receives NIH Grant for the Development of its Novel Antimicrobial …
-- Funding supports unique approach for fighting multi-drug resistant Acinetobacter baumannii (AB) -- Clinical trial preparations of OMN6 under way JERUSALEM, Israel, August 31, 2021 -- Omnix Medical, a Jerusalem-based biopharmaceutical company developing next-generation anti-infectives for the treatment of life-threatening infections, has received a grant by the U.S. National Institutes of Health (NIH) for the development of its first-in-class antimicrobial peptide OMN6 targeting Acinetobacter baumannii (AB). Acinetobacter baumannii are multi-drug resistant
The National Institutes of Health (NIH) Awards Adelphi University Professors Nea …
The National Institutes of Health (NIH) has awarded Adelphi University Associate Professors Brian Stockman, Ph.D. and Melissa VanAlstine-Parris, Ph.D., both in the Department of Chemistry, a federal grant for $310,934. One of the main goals of the project is to immerse undergraduate students into cutting-edge scientific research including hands-on use of NMR spectroscopy instrumentation, medicinal chemistry and Trichomonas vaginalis cell biology. The award became active on June 1, 2017 and
BARDA, NIH and Janssen to Present on Antimicrobial Resistance at Superbugs USA t …
SMi are delighted to announce the expansion of their antimicrobial portfolio of events across the Atlantic with the release of Superbugs & Superdrugs USA, complementing the Group’s Superbugs & Superdrugs European conference which has been running for the past 18 years. With pending confirmations from PAHO/WHO and Astra Zeneca, SMi Group have worked closely with a panel of speakers to present an agenda that will look to address key issues
Dr. James Gulley - NCI, NIH to speak at the Cancer Immunotherapy Congress in Bos …
Dr. James Gulley, an internationally recognized expert in cancer immunotherapy has joined the speaker panel for the Cancer Immunotherapy Congress organized by Markets and Markets Conferences. The congress scheduled for 19th – 20th May 2016 in Boston, USA, will gather scientists, academicians and professionals from Pharmaceutical, Bio-pharmaceutical, Bio-technology companies and Research institutes working in Drug Discovery, Drug Screening, Oncology R&D, Cancer Immunotherapy/ Immuno-oncology and Immunotherapy R&D. Dr. Gulley serves within